Safety of Helicobacter pylori eradication therapy in patients with inflammatory bowel disease

Safety of Helicobacter pylori eradication therapy in patients with inflammatory bowel disease - Relationship of inflammatory bowel disease and Helicobacter pylori infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017105

Enrollment

100

Registered

2015-04-13

Start date

2015-04-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (Ulcerative colitis, Crohn&#39

Interventions

Eradication therapy for IBD patients with Helicobacter pylori infection.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with IBD under remission stage (Ulcerative colitis: partial mayo score<3, Crohn's disease: CDAI<150)

Exclusion criteria

Exclusion criteria: 1) The patient who is not infected by Helicobacter pylori 2) The patient who is not under remission stage of IBD 3) The patient who is required the change of treatment for IBD during observation period 4) The patient who has allergy for penicillin 5) The patient who has malignant disease 6) The patient who has been already eradicated Helicobacter pylori 7) The patient who dose not agree with this study 8) The patinets who are determiend not to be appropriate for this study

Design outcomes

Primary

Measure	Time frame
Influence of Helicobacter pylori eradication therapy for IBD disease activity.	—

Secondary

Measure	Time frame
Specifications of Helicobacter pylori infection in patients with IBD.	—

Countries

Japan

Contacts

Public ContactToshihiko Okada

Osaka medical collage Second department of internal medicine

toshi52omc@yahoo.co.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026